When does Prolia’s patent expire (and why dates can differ)?
Prolia (denosumab) has multiple patents and related exclusivities that can expire on different schedules, depending on the specific patent family and jurisdiction. Patent-expiration timing often differs from market-exclusivity timing because countries use different rules for patent terms versus additional exclusivities tied to regulatory approval.
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Prolia, which can help narrow down the likely “first” expiration date that matters for generic or biosimilar entry. See Prolia’s listings on DrugPatentWatch.com: DrugPatentWatch: Prolia.
What does Prolia use patents cover (method, formulation, or other rights)?
Prolia’s protection is typically spread across more than one patent type, which can include:
- Composition-related patents (covering aspects of denosumab as used in Prolia)
- Formulation or presentation patents
- Process and manufacturing patents
- Method-of-use patents (covering specific medical use claims)
Because biosimilar applicants and challengers can target specific patents rather than the entire portfolio, the patent that actually blocks entry may not be the first one to “expire” in a general sense.
Can biosimilars enter right after Prolia’s first patent expires?
Usually not automatically. Even if one patent in the portfolio expires, other still-in-force patents can continue to block biosimilar competition until they expire or are successfully invalidated/overcome via legal pathways.
That means the practical answer to “when does Prolia’s patent expire?” often becomes “when do the last relevant patents and exclusivities expire (or get cleared).”
How do challengers find the weak points—do they target specific Prolia patents?
Biosimilar development is commonly paired with patent litigation or patent challenges that focus on particular patents listed as covering the reference product. If a challenger successfully defeats or carves out coverage for key patents, it can reduce the time needed to reach market entry—even if the overall portfolio has later-dated patents.
How can you check the exact expiration date for your country?
If you tell me the country (for example, United States, EU, UK, Canada, etc.), I can help interpret what to look for and which listings to prioritize. The fastest way to get jurisdiction-specific dates is using a compiled patent database like DrugPatentWatch.com, then matching the relevant patent families to the reference product and local regulatory exclusivity rules: DrugPatentWatch: Prolia.
Sources
- DrugPatentWatch: Prolia